Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
TER
0,35% p.a.
Distribution policy
Ausschüttend
Replication
Physisch
Fund size
CHF 63 m
Inception Date
5. März 2018
Holdings
250
Overview
Description
Der iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) bildet den Nasdaq Biotechnology Index nach. Der Nasdaq Biotechnology Index bietet Zugang zu Biotechnologie-Unternehmen, die an der Nasdaq gelistet sind.
Documents
Chart
Basics
Data
| Investment approach | Long-only |
| Index | Nasdaq Biotechnology |
| Investment focus | Aktien, USA, Gesundheitswesen |
| Fund size | CHF 63 m |
| Total expense ratio | 0,35% p.a. |
| Replication | Physical (Optimized sampling) |
| Legal structure | ETF |
| Sustainability | Nein |
| Fund currency | USD |
| Currency hedged | No |
| Inception/ Listing Date | 5. März 2018 |
| Distribution policy | Distributing |
| Distribution frequency | Semi annually |
| Fund domicile | Irland |
| Fund Provider | iShares |
Tax status
| Switzerland | ESTV Reporting |
| Germany | 30% Teilfreistellung |
| Austria | Meldefonds |
| UK | UK Reporting |
| Italy | 26,0% |
| Fund Structure | Open-ended Investment Company (OEIC) |
| UCITS compliance | Yes |
| Administrator | State Street Fund Services (Ireland) Limited |
| Investment Advisor | |
| Custodian Bank | State Street Custodial Services (Ireland) Limited |
| Revision Company | Deloitte |
| Fiscal Year End | 31. Mai |
| Swiss representative | BlackRock Asset Management Schweiz AG |
| Swiss paying agent | State Street Bank International GmbH, Munich, Zurich Branch |
| Indextype | Total return index |
| Swap counterparty | - |
| Collateral manager | Bank of New York Mellon|Euroclear|JP Morgan|State Street Bank |
| Securities lending | Yes |
| Securities lending counterparty | Barclays Bank Plc|Barclays Capital Securities Ltd.|BNP Paribas Arbitrage SNC|BNP Paribas SA|Citigroup Global Markets Ltd|Citigroup Inc|Credit Suisse Securities (Europe) Ltd.|Deutsche Bank AG|Goldman Sachs International|HSBC Bank Plc|J.P. Morgan Securities Plc|JP Morgan Chase & Co|Macquarie Bank Limited|Merrill Lynch International|Morgan Stanley & Co. International Plc|Nomura International Plc|Skandinaviska Enskilda Banken AB|Societe Generale SA|The Bank of Nova Scotia|UBS AG |
Similar ETFs
This section provides you with information on other ETFs with a similar investment focus to the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
Similar ETFs via ETF search
Similar ETFs via investment guides
How do you like our ETF profile? Here you'll find our Questionnaire.
Holdings
Below you find information about the composition of the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
Top 10 Holdings
Weight of top 10 holdings
out of 250
44,15%
| Amgen, Inc. | 8,66% |
| Vertex Pharmaceuticals | 8,26% |
| Gilead Sciences, Inc. | 7,39% |
| Regeneron Pharmaceuticals, Inc. | 5,33% |
| Moderna | 3,60% |
| Revolution Medicines | 2,83% |
| Illumina, Inc. | 2,09% |
| Alnylam Pharmaceuticals | 2,08% |
| Biogen | 2,07% |
| argenx | 1,84% |
As of 31.08.2026
ETF Savings plan offers
Hier findest du Informationen zu den aktuell verfügbaren Sparplan-Angeboten für diesen ETF. Mithilfe der Tabelle kannst du alle Sparplan-Angebote für die gewählte Sparrate vergleichen.
Source: justETF Research; as of 10/2026. The offers are sorted in the following way: 1. Rating 2. Execution fee 3. Number of ETF savings plans. In addition to the fees charged by online brokers, additional costs may apply. The stated fees are thus exclusive of standard market spreads, commissions, product costs and third-party fees. Please note: No guarantee can be given for the completeness, correctness and accuracy of the content listed. The information on the online brokers' homepages is decisive. Investments in securities involve risks.
*Affiliate link
** Important note: We are part of the Scalable Group since 2021 and are a wholly owned subsidiary of Scalable AG. This means that we are economically connected, but operate with editorial independence. Conflicts of interest are avoided because brokers — including Scalable — are evaluated according to uniform, objective criteria. You can view these in our transparent rating system. Ultimately, it’s up to you to decide how and with whom you want to invest.
*Affiliate link
** Important note: We are part of the Scalable Group since 2021 and are a wholly owned subsidiary of Scalable AG. This means that we are economically connected, but operate with editorial independence. Conflicts of interest are avoided because brokers — including Scalable — are evaluated according to uniform, objective criteria. You can view these in our transparent rating system. Ultimately, it’s up to you to decide how and with whom you want to invest.
Performance
Die Wertentwicklungsangaben beinhalten Ausschüttungen/Dividenden (falls vorhanden). Es wird standardmässig die Gesamtperformance des ETF angezeigt.
Returns overview
| YTD | +30.09% |
| 1 month | +0.12% |
| 3 months | +10.66% |
| 6 months | +27.75% |
| 1 year | +40.10% |
| 3 years | +80.93% |
| 5 years | +32.79% |
| Since inception (MAX) | +80.43% |
| 2025 | +16.04% |
| 2024 | +7.05% |
| 2023 | -5.12% |
| 2022 | -9.61% |
Monthly returns in a heat map
Dividends
Current dividend yield
| Aktuelle Ausschüttungsrendite | 0,21% |
| Dividends (last 12 months) | CHF 0,02 |
Historic dividend yields
| Period | Dividend in CHF | Dividend yield in % |
|---|---|---|
| 1 Jahr | CHF 0,02 | 0,29% |
| 2025 | CHF 0,02 | 0,44% |
| 2024 | CHF 0,03 | 0,48% |
| 2023 | CHF 0,02 | 0,39% |
| 2022 | CHF 0,03 | 0,41% |
Dividend yield contribution
Monthly dividends
Risk
Risk metrics in this section:
- Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
- Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
- Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.
Risk overview
| Risk indicator |
Lower risk Higher risk |
| Volatility 1 year | 22.20% |
| Volatility 3 years | 21.78% |
| Volatility 5 years | 23.06% |
| Return per risk 1 year | 1.81 |
| Return per risk 3 years | 1.00 |
| Return per risk 5 years | 0.25 |
| Maximum drawdown 1 year | -7.80% |
| Maximum drawdown 3 years | -27.59% |
| Maximum drawdown 5 years | -32.31% |
| Maximum drawdown since inception | -36.03% |
Rolling 1 year volatility
Stock exchange
Listings
| Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| gettex | EUR | OM3E | - - | - - | - |
| London Stock Exchange | USD | BTEE | BTEE LN INAVBTDU | BTTE.L |
Further information
Latest articles
Frequently asked questions
What is the name of OM3E?
The name of OM3E is iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
What is the ticker of iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)?
The primary ticker of iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) is OM3E.
What is the ISIN of iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)?
The ISIN of iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) is IE00BDZVHG35.
What are the costs of iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)?
The total expense ratio (TER) of iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) amounts to 0,35% p.a.. These costs are withdrawn continuously from the fund assets and already included in the performance of the ETF. You don't have to pay them separately. Please have a look at our article for more information about the cost of ETFs.
Is iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) paying dividends?
Yes, iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) is paying dividends. Usually, the dividend payments take place halbjährlich for iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
What's the fund size of iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)?
The fund size of iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) is 69m Euro. See the following article for more information about the size of ETFs.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.